Patents by Inventor James Neef

James Neef has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators
    Patent number: 11919911
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 5, 2024
    Assignee: Novartis AG
    Inventors: Sung David C. Kim, Zaixing Li, Chui Lu, Danuta Lubicka, James Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11820778
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: November 21, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20230212139
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11548865
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 10, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20220411435
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: August 8, 2022
    Publication date: December 29, 2022
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11485742
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: November 1, 2022
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Ca1.2 activators
    Patent number: 11453679
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Thomas Charles Caya, James Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS
    Publication number: 20210395261
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 23, 2021
    Inventors: Sung David C. Kim, Zaixing Li, Chui Lu, Danuta Lubicka, James Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
    Publication number: 20210387995
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 16, 2021
    Inventors: Thomas Charles Caya, James Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210130365
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 6, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210107889
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 15, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 10112926
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 30, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Publication number: 20180243297
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 26, 2018
    Publication date: August 30, 2018
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 10004732
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 9862711
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: January 9, 2018
    Assignee: NOVARTIS AG
    Inventors: Benjamin Richard Bellenie, Ian Bruce, Andrew James Culshaw, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170042889
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170037032
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 9, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170029414
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 2, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Ian BRUCE, Andrew James CULSHAW, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • Organic compounds
    Patent number: 7994203
    Abstract: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: August 9, 2011
    Assignee: Novartis AG
    Inventors: Ian Bruce, Andrew James Culshaw, Nicholas James Devereux, François Gessier, Jeffrey McKenna, James Neef, Helen Elizabeth Oakman
  • Organic compounds
    Publication number: 20100035874
    Abstract: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Application
    Filed: August 3, 2009
    Publication date: February 11, 2010
    Inventors: Ian Bruce, Andrew James Culshaw, Nicholas James Devereux, François Gessier, Jeffrey Mc Kenna, James Neef, Helen Elizabeth Oakman